Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

US10793547B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Alexander Russell Abela · San Diego, US
• Timothy Alcacio · San Diego, US
• Corey Anderson · San Diego, US
• Paul Angell · Carlsbad, US
• Minson Baek · San Diego, US
• Jeremy J. Clemens · San Diego, US
• Thomas Cleveland · San Diego, US
• Lori Ann Ferris · Medford, US
• Peter Diederik Jan Grootenhuis · San Diego, US
• Raymond Stanley Gross · Poway, US
• Anton V. Gulevich · San Diego, US
• Sara S. Hadida Ruah · Village of La Jolla, US
• Clara Kuang-Ju Hsia · San Diego, US
• Robert Michael Hughes · San Diego, US
• Pramod Joshi · San Diego, US
• Ping Kang · San Diego, US
• Ali Keshavarz-Shokri · San Diego, US
• Haripada Khatuya · San Diego, US
• Paul Krenitsky · San Diego, US
• Jason McCartney · Encinitas, US
• Mark Miller · San Diego, US
• Prasuna Paraselli · San Diego, US
• Fabrice Pierre · Cugnaux, FR
• Yi-Qun Shi · East Brunswick Township, US
• Muna Shrestha · Belmont, US
• David Andrew Siesel · San Diego, US
• Kathy Stavropoulos · Quincy, US
• Andreas P. Termin · Encinitas, US
• Fredrick Van Goor · San Diego, US
• Johnny Uy · San Diego, US

Key dates

• Filing date: Dec 8, 2017
• Grant date: Oct 6, 2020
• Expiry date: Dec 8, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.